Literature DB >> 2821605

The role of the oncogene c-myc in sporadic large bowel cancer and familial polyposis coli.

P G Rothberg1.   

Abstract

The human myc gene is homologous to the v-myc gene, which was discovered in the avian oncogenic retrovirus MC29. Abnormally high expression of the cellular oncogenes is suspected to be involved in nonviral carcinogenesis. This article reviews the evidence that elevated expression of the human myc gene is involved in sporadic colon carcinoma and familial polyposis coli. The abundance of myc RNA and protein is frequently higher in colorectal cancer than in normal mucosa. The mechanism of this altered expression is obscure because the structure and quantity of myc DNA are very rarely disturbed. The COLO320 cell line is discussed as one unusual example of myc DNA rearrangement and amplification. There is a correlation between tumor-specific elevated myc RNA level and location in the bowel; tumors distal to the transverse colon are more likely to have elevated myc expression. The site distribution of unselected colorectal malignancies with an elevated myc RNA level is similar to the site distribution of familial polyposis coli tumors. With this observation it is suggested that elevated myc RNA may be a marker of a distinct type of colorectal cancer that involves the same genetic events as precede familial polyposis coli cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821605     DOI: 10.1002/ssu.2980030305

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  8 in total

1.  Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3β and F-box and WD repeat domain-containing 7.

Authors:  Ji Hoon Jung; Deok-Beom Jung; Hyunseok Kim; Hyemin Lee; Shi-Eun Kang; Sanjay K Srivastava; Miyong Yun; Sung-Hoon Kim
Journal:  Oncogene       Date:  2018-04-09       Impact factor: 9.867

2.  Differences in protein expression and gene amplification of cyclins between colon and rectal adenocarcinomas.

Authors:  Rolf Aamodt; Kristin Jonsdottir; Solveig Norheim Andersen; Johan Bondi; Geir Bukholm; Ida R K Bukholm
Journal:  Gastroenterol Res Pract       Date:  2009-12-15       Impact factor: 2.260

3.  Development and endoscopic appearance of colorectal tumors are characterized by the expression profiles of miRNAs.

Authors:  Yoshihito Nakagawa; Yukihiro Akao; Tomomitsu Tahara; Hiromi Yamashita; Mitsuo Nagasaka; Tomoyuki Shibata; Naoki Ohmiya
Journal:  Med Mol Morphol       Date:  2018-03-21       Impact factor: 2.309

4.  Cell cycle kinetic analysis of colorectal neoplasms using a new automated immunohistochemistry-based cell cycle detection method.

Authors:  Ayako Tomono; Tomoo Itoh; Emmy Yanagita; Naoko Imagawa; Yoshihiro Kakeji
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

5.  Relationship between expression of onco-related miRNAs and the endoscopic appearance of colorectal tumors.

Authors:  Yoshihito Nakagawa; Yukihiro Akao; Kohei Taniguchi; Akemi Kamatani; Tomomitsu Tahara; Toshiaki Kamano; Naoko Nakano; Naruomi Komura; Hirokazu Ikuno; Takafumi Ohmori; Yasutaka Jodai; Masahiro Miyata; Mistuo Nagasaka; Tomoyuki Shibata; Naoki Ohmiya; Ichiro Hirata
Journal:  Int J Mol Sci       Date:  2015-01-09       Impact factor: 5.923

6.  LIN28B promotes colon cancer migration and recurrence.

Authors:  Minghui Pang; Gang Wu; Xiaolin Hou; Nengyi Hou; Liqin Liang; Guiqing Jia; Ping Shuai; Bin Luo; Kang Wang; Guoxin Li
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

7.  Repurposing Tranexamic Acid as an Anticancer Agent.

Authors:  Mary E Law; Bradley J Davis; Amanda F Ghilardi; Elham Yaaghubi; Zaafir M Dulloo; Mengxiong Wang; Olga A Guryanova; Coy D Heldermon; Stephan C Jahn; Ronald K Castellano; Brian K Law
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

Review 8.  Is mucinous carcinoma of the colorectum a distinct genetic entity?

Authors:  C Hanski
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.